Abstract 5901
Background
Cabozantinib (C) is an inhibitor of multiple receptor tyrosine kinases involved in tumor cell proliferation, neovascularization, and immune cell regulation, including MET, VEGFRs, and TAM family of kinases (TYRO3, MER, and AXL). Preclinical/clinical studies suggest that C promotes an immune-permissive environment that may facilitate synergistic effects with checkpoint inhibitors. This Phase 1b study evaluates C in combination with the programmed death ligand (PD-L1) targeting antibody atezolizumab (A) in pts with solid tumors (NCT03170960).
Methods
Safety and clinical activity of C (2 dose levels: 40 mg, 60 mg QD) + A (1200 mg Q3W) administered in 3-week cycles were evaluated in a 3 + 3 dose escalation design. Safety data of all pts and criteria for dose limiting toxicity (DLT) determined the recommended dose (RD) for a subsequent expansion stage. Tumor response was assessed by CT/MRI and bone scan (RECIST v 1.1).
Results
12 pts with treatment-naïve advanced RCC (mostly clear-cell subtype) were treated in the dose escalation stage (6 at each dose level). At data cutoff, all pts were actively receiving study treatment (range, 3–12 cycles). There were no DLTs or serious adverse events (AEs) in either C+A dose cohort. Most AEs were Grade 1/2 including immune-related AEs. Grade 3 AEs included 3 events of hypertension, 2 events each of diarrhea and hypophosphatemia, and 1 pulmonary embolism. There were no Grade 4/5 AEs. Among 10 pts investigator-assessed confirmed ORR was 50% (1 CR, 4 PRs); 2 additional pts had unconfirmed PRs with only 1 tumor assessment at data cut-off.
Conclusions
C+A is well tolerated and shows encouraging anti-tumor activity in advanced RCC. C 40 mg QD + A 1200 mg Q3W was selected as the RD for expansion in multiple solid tumor cohorts including RCC.
Clinical trial identification
NCT03170960.
Legal entity responsible for the study
Exelixis, Inc.
Funding
Exelixis, Inc.
Editorial Acknowledgement
Disclosure
N. Agarwal: Consulting or advisory role: Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono, BMS, AstraZeneca, Astellas. U. Vaishampayan: Honoraria: Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Janssen, Novartis, Pfizer, Sanofi; Consulting or advisory role: Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech/Roche, Novartis, Pfizer; Speakers' bureau: Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech/Roche, Novartis, Pfizer, Sanofi; Research funding: Astellas Pharma, Bristol-Myers Squibb, Exelixis, Novartis, Pfizer. M. Green, F. di Nucci: Employee: Genentech. P-Y. Chang: Employee of Exelixis Inc. C. Scheffold: Employee of and owns stock in Exelixis, Inc. S. Pal: Honoraria: Astellas Pharma, Medivation, Novartis; Consulting or advisory role: Aveo, Bristol-Myers Squibb, Exelixis, Genentech, Myriad Pharmaceuticals, Novartis, Pfizer; Research funding: Medivation.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract